Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
Recruiting
1,800 enrolled
Testicular Tissue Cryopreservation for Fertility Preservation
Phase NA Recruiting
1,500 enrolled
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Phase 2 Recruiting
83 enrolled
MYOPK
Phase 3 Recruiting
276 enrolled
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
Phase 3 Recruiting
120 enrolled
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Phase 1/2 Recruiting
28 enrolled
Multiparametric Image Analysis and Correlation With Outcomes in Lung Cancer Screening and Early Stage Lung Cancer
Recruiting
2,000 enrolled
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Phase 2 Recruiting
200 enrolled
Vaginal Cuff Brachytherapy Fractionation Study
Phase 3 Recruiting
258 enrolled
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
Phase 3 Recruiting
60 enrolled
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Phase 2 Recruiting
314 enrolled
GBM AGILE
Phase 2/3 Recruiting
2,250 enrolled
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Phase 2 Recruiting
42 enrolled
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Phase 3 Recruiting
1,210 enrolled
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Phase 3 Recruiting
247 enrolled
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Phase 2/3 Recruiting
138 enrolled
Spermatogonial Stem Cell (SSC) Transplant and Testicular Tissue Grafting
Phase NA Recruiting
10 enrolled
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Phase 2 Recruiting
70 enrolled
Postfossa ICP
Recruiting
12 enrolled
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
Phase 1 Recruiting
20 enrolled
Cerebrospinal Fluid Biomarkers for Brain Tumors
Recruiting
400 enrolled
SCOUT-1
Recruiting
750 enrolled
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Phase 2 Recruiting
152 enrolled
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
Phase 2 Recruiting
164 enrolled
rbliqbx
Recruiting
800 enrolled
PRECEDE
Recruiting
20,000 enrolled
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Phase 1/2 Recruiting
246 enrolled
PancreasScan
Recruiting
1,395 enrolled
CaDAnCe-101
Phase 1/2 Recruiting
614 enrolled
Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial
Phase 1 Recruiting
28 enrolled
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Phase 1/2 Recruiting
132 enrolled
MAHOGANY
Phase 3 Recruiting
780 enrolled
PARPAML
Phase 1 Recruiting
34 enrolled
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
Phase 1/2 Recruiting
55 enrolled
PARTIAL
Phase NA Recruiting
600 enrolled
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
Phase 2 Recruiting
42 enrolled
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Phase 3 Recruiting
360 enrolled
Lopinavir/Ritonavir in PLWH With High-Grade AIN
Phase 1 Recruiting
21 enrolled
CEMI-LUNG
Recruiting
500 enrolled
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Phase 1 Recruiting
398 enrolled
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
Phase 1 Recruiting
36 enrolled
Amelia-1
Phase 1/2 Recruiting
52 enrolled
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Phase 1/2 Recruiting
265 enrolled
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
Phase 2 Recruiting
165 enrolled
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Phase 2 Recruiting
153 enrolled
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
Phase 1 Recruiting
20 enrolled
iPRRT
Phase 2 Recruiting
18 enrolled
A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...
Phase NA Recruiting
60 enrolled
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Phase 2 Recruiting
30 enrolled
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Phase 3 Recruiting
1,875 enrolled